19. Kobayashi S, Murata K, Shibuya H, et al. A distinct human CD4+ T cell subset that secretes CXCL13 in rheumatoid synovium. Arthritis Rheum, 2013, 65(12):3063-3072.
[2]
22. Sambandam Y, Sundaram K, Liu A, et al. CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment. Oncogene, 2013, 32(1):97-105.
[3]
18. Silva JS, Andrade AC, Santana CC, et al. Low CXCL13 expression, splenic lymphoid tissue atrophy and germinal center disruption in severe canine visceral leishmaniasis. PLoS One, 2012, 7(1):e29103-29113.
[4]
5. Greisen S, Schelde K, Rasmussen T, et al. CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic window of opportunity. Arthritis Res Ther, 2014, 16(5):434.
[5]
6. Jones JD, Hamilton BJ, Challener GJ, et al. Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels. Arthritis Res Ther, 2014, 16(2):R103.
[6]
7. Platas J, Guillén MI, Del Caz MD, et al. Conditioned media from adipose-tissue-derived mesenchymal stem cells downregulate degradative mediators induced by interleukin-1β in osteoarthritic chondrocytes. Mediators Inflamm, 2013:354014.
[7]
1. Blagojevic M, Jinks C, Jeffery A, et al. Risk factors for onset of osteoarthritis of the knee in older adults:a systematic review and meta-analysis. Osteoarthritis Cartilage, 2010, 18(1):24-33.
3. Braunersreuther V, Viviani GL, Mach F, et al. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol, 2012, 18(8):727-735.
[10]
4. Bugatti S, Manzo A, Vitolo B, et al. High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. Rheumatology (Oxford), 2014, 53(10):1886-1895.
[11]
8. Liu C, Weng YG, Yuan TX, et al. CXCL12/CXCR4 signal axis plays an important role in mediating bone morphogenetic protein 9-induced osteogenic differentiation of mesenchymal stem cells. Int J Med Sci, 2013, 10(9):1181-1192.
[12]
9. Forestier R, Francon A, Briole V, et al. Prevalence of generalized osteoarthritis in a population with knee osteoarthritis. Joint Bone Spine, 2011, 78(3):275-278.
[13]
10. Yamairi F, Utsumi H, Ono Y, et al. Expression of vascular endothelial growth factor (VEGF) associated with histopathological changes in rodent models of osteoarthritis. J Toxicol Pathol, 2011, 24(2):137-142.
[14]
11. Sartori-Cintra AR, Mara CS, Argolo DL, et al. Regulation of hypoxia-inducible factor-1a(HIF-1α)expression by interleukin-1β(IL-1β), insulin-like growth factors I (IGF-I) and Ⅱ (IGF-Ⅱ) in human osteoarthritic chondrocytes. Clinics (Sao Paulo), 2012, 67(1):35-40.
[15]
12. Nagahara M, Waguri-Nagaya Y, Yamagami T, et al. TNF-alphainduced aquaporin 9 in synoviocytes from patients with OA and RA. Rheumatology (Oxford), 2010, 49(5):898-906.
15. Wojdasiewicz P, Poniatowski LA, Kotela A, et al. The chemokine CX3CL1(fractalkine) and its receptor CX3CR1:occurrence and potential role in osteoarthritis. Arch Immunol Ther Exp (Warsz), 2014, 62(5):395-403.
[19]
16. Shen W, Chen J, Zhu T, et al. Intra-articular injection of human meniscus stem/progenitor cells promotes meniscus regeneration and ameliorates osteoarthritis through stromal cell-derived factor-1/CXCR4-mediated homing. Stem Cells Transl Med, 2014, 3(3):387-394.
[20]
17. Kowarik MC, Cepok S, Sellner J, et al. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation, 2012, 9:93-104.
[21]
20. Halvorsen B, Smedbakken LM, Michelsen AE, et al. Activated platelets promote increased monocyte expression of CXCR5 through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects of CXCL13. Atherosclerosis, 2014, 234(2):352-359.
[22]
21. Yuvaraj S, Griffin AC, Sundaram K, et al. A novel function of CXCL13 to stimulate RANK ligand expression in oral squamous cell carcinoma cells. Mol Cancer Res, 2009, 7(8):1399-1407.
